Up-regulation of miR-20a weakens inflammation and apoptosis in high-glucose-induced renal tubular cell mediating diabetic kidney disease by repressing CXCL8 expression

References

• Assmann, T.S., et al., 2018. MicroRNAs and diabetic kidney disease: systematic review and bioinformatic analysis. Molecular and cellular endocrinology, 477, 90–102.
   PubMed Web of Science ®Google Scholar
• Bălăşescu, E., et al., 2016. Immunohistochemical aspects of cell death in diabetic nephropathy. Romanian journal of internal medicine, 54 (1), 54–62.
   PubMed Web of Science ®Google Scholar
• Cai, J., et al., 2013. MicroRNA-374a activates Wnt/β-catenin signaling to promote breast cancer metastasis. The journal of clinical investigation, 123 (2), 566–579.
   PubMed Web of Science ®Google Scholar
• Campbell, L.M., Maxwell, P.J., and Waugh, D.J.J., 2013. Rationale and means to target pro-inflammatory interleukin-8 (CXCL8) signaling in cancer. Pharmaceuticals, 6 (8), 929–959.
   Google Scholar
• Chan, L.P., et al., 2017. IL-8 promotes inflammatory mediators and stimulates activation of p38 MAPK/ERK-NF-κB pathway and reduction of JNK in HNSCC. Oncotarget, 8 (34), 56375–56388.
   PubMedGoogle Scholar
• Cui, S., et al., 2017. CXCL8 antagonist improves diabetic nephropathy in male mice with diabetes and attenuates high glucose-induced mesangial injury. Endocrinology, 158 (6), 1671–1684.
   PubMed Web of Science ®Google Scholar
• Gao, S.M., et al., 2011. MiR-15a and miR-16-1 inhibit the proliferation of leukemic cells by down-regulating WT1 protein level. Journal of experimental & clinical cancer research, 30 (1), 110.
   PubMedGoogle Scholar
• Huang, Z., et al., 2018. The enhancer RNA lnc-SLC4A1-1 epigenetically regulates unexplained recurrent pregnancy loss (URPL) by activating CXCL8 and NF-kB pathway. EBioMedicine, 38, 162–170.
   PubMed Web of Science ®Google Scholar
• Kato, M. and Natarajan, R., 2015. MicroRNAs in diabetic nephropathy: functions, biomarkers, and therapeutic targets. Annals of the New York Academy of Sciences, 1353, 72–88.
   PubMed Web of Science ®Google Scholar
• Kumar, D., Robertson, S., and Burns, K.D., 2004. Evidence of apoptosis in human diabetic kidney. Molecular and cellular biochemistry, 259 (1–2), 67–70.
   PubMed Web of Science ®Google Scholar
• Li, H., et al., 2017. MicroRNA-25 inhibits high glucose-induced apoptosis in renal tubular epithelial cells via PTEN/AKT pathway. Biomedicine & pharmacotherapy, 96, 471–479.
   PubMed Web of Science ®Google Scholar
• Li, M.Q., et al., 2012. CXCL8 enhances proliferation and growth and reduces apoptosis in endometrial stromal cells in an autocrine manner via a CXCR1-triggered PTEN/AKT signal pathway. Human reproduction, 27 (7), 2107–2116.
   PubMed Web of Science ®Google Scholar
• Li, R., et al., 2014. MicroRNAs in diabetic kidney disease. International journal of endocrinology, 2014 (10), 593956.
   PubMedGoogle Scholar
• Pichler, R., et al., 2016. Immunity and inflammation in diabetic kidney disease: translating mechanisms to biomarkers and treatment targets. American journal of physiology renal physiology, 312 (4), F716–F731.
   PubMed Web of Science ®Google Scholar
• Qian, X., et al., 2018. MicroRNA-134-5p promotes high glucose-induced podocyte apoptosis by targeting bcl-2. American journal of translational research, 10 (3), 989–997.
   PubMed Web of Science ®Google Scholar
• Reidy, K., et al., 2014. Molecular mechanisms of diabetic kidney disease. Journal of clinical investigation, 124 (6), 2333–2340.
   PubMed Web of Science ®Google Scholar
• Runtsch, M.C., et al., 2019. Anti-inflammatory microRNA-146a protects mice from diet-induced metabolic disease. PLoS genetics, 15 (2), e1007970.
   PubMed Web of Science ®Google Scholar
• Shi, Y. and Hu, F.B., 2014. The global implications of diabetes and cancer. Lancet, 383 (9933), 1947–1948.
   PubMed Web of Science ®Google Scholar
• Shinji, H., et al., 2006. Eicosapentaenoic acid ameliorates diabetic nephropathy of type 2 diabetic KKAy/Ta mice: involvement of MCP-1 suppression and decreased ERK1/2 and p38 phosphorylation. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association, 21 (3), 605.
   PubMed Web of Science ®Google Scholar
• Signs, S.A., et al., 2018. Stromal miR-20a controls paracrine CXCL8 secretion in colitis and colon cancer. Oncotarget, 9 (16), 13048–13059.
   PubMedGoogle Scholar
• Simpson, K., et al., 2016. MicroRNAs in diabetic nephropathy: from biomarkers to therapy. Current diabetes reports, 16 (3), 1–7.
   PubMed Web of Science ®Google Scholar
• Song, G., et al., 2018. Astragaloside IV ameliorates early diabetic nephropathy by inhibition of MEK1/2-ERK1/2-RSK2 signaling in streptozotocin-induced diabetic mice. Journal of international medical research, 46 (7), 2883–2897.
   PubMed Web of Science ®Google Scholar
• Sun, Y., et al., 2015. Signaling pathway of MAPK/ERK in cell proliferation, differentiation, migration, senescence and apoptosis. Journal of receptor and signal transduction research, 35 (6), 600–604.
   PubMed Web of Science ®Google Scholar
• Taneda, S., et al., 2010. Eicosapentaenoic acid restores diabetic tubular injury through regulating oxidative stress and mitochondrial apoptosis. American journal of physiology renal physiology, 299 (6), 1451–1461.
   Web of Science ®Google Scholar
• Wang, X., et al., 2017. MicroRNA-20b contributes to high glucose-induced podocyte apoptosis by targeting SIRT7. Molecular medicine reports, 16 (4), 5667–5674.
   PubMed Web of Science ®Google Scholar
• Waugh, D.J. and Wilson, C., 2008. The interleukin-8 pathway in cancer. Clinical cancer research: an official journal of the American Association for Cancer Research, 14 (21), 6735–6741.
   PubMed Web of Science ®Google Scholar
• Yao, T., et al., 2018. MiR-874 alleviates renal injury and inflammatory response in diabetic nephropathy through targeting toll-like receptor-4. Journal of cellular physiology, 234 (1), 871–879.
   PubMed Web of Science ®Google Scholar
• Ye, D., et al., 2018. Plasma miR-17, miR-20a, miR-20b and miR-122 as potential biomarkers for diagnosis of NAFLD in type 2 diabetes mellitus patients. Life sciences., 208, 201–207.
   PubMed Web of Science ®Google Scholar
• Yoshimura, T., et al., 1987. Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines. Proceedings of the National Academy of Sciences of the United States of America, 84 (24), 9233–9237.
   PubMed Web of Science ®Google Scholar
• You-Jie, L.I., et al., 2010. Inhibition of 293T cell proliferation by blocking miR-20 and miR-106 expression with antisense RNA. Chinese journal of pathophysiology, 26 (9), 1665–1669.
   Google Scholar
• Zhang, J.L., et al., 2013. Gabapentin reduces allodynia and hyperalgesia in painful diabetic neuropathy rats by decreasing expression level of Nav1.7 and p-ERK1/2 in DRG neurons. Brain research, 1493 (1), 13–18.
   PubMedGoogle Scholar
• Zhao, B., et al., 2016. MicroRNA-23b targets Ras GTPase-activating protein SH3 domain-binding protein 2 to alleviate fibrosis and albuminuria in diabetic nephropathy. Journal of the American Society of Nephrology, 27 (9), 2597–2608.
   PubMed Web of Science ®Google Scholar
• Zhong, X., et al., 2013. MiR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes. Diabetologia, 56 (3), 663–674.
   PubMed Web of Science ®Google Scholar